DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study

Information source: Gauda, Estelle B., M.D.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mechanical Ventilation Complication

Intervention: intermittent IV CLON (Drug)

Phase: Phase 1/Phase 2

Status: Not yet recruiting

Sponsored by: Gauda, Estelle B., M.D.

Official(s) and/or principal investigator(s):
Estelle Ezell, MD, Principal Investigator, Affiliation: Johns Hopkins University

Overall contact:
Estelle B Gauda, MD, Phone: 410-614-0151, Email: egauda@jhmi.edu


Critically ill infants and children who are mechanically ventilated are often given large doses of opiates and benzodiazepines to provide analgesia-sedation. These drugs significantly cause tolerance and dependence, depresses the drive to breathe, and thus prolongs the need for mechanical ventilation and the associated complications. We propose IV CLON could be used as effectively as DEX.

Clinical Details

Official title: Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Sedation

Secondary outcome:

Frequency of cardiovascular occurrences

Length of stay

Detailed description: All critically ill mechanically ventilated infants and children receive intravenous analgesic-sedatives which often include opiates and benzodiazepines (BENZO). Undesirable side effects from these drugs include respiratory depression, tolerance and dependence. Alpha 2-adrenergic receptor agonists, dexmedetomidine (DEX) and clonidine (CLON) have excellent sedative-analgesics effects, do not cause respiratory depression and are opiate/BENZO sparing. While both are efficacious in providing sedation, several factors have led to a substantial increase in the use of the newer drug DEX over the more established drug CLON in adults, children and infants. However, studies to guide therapy and dosing for infants and children are lacking. While these infants and children do require less opiate/BENZO therapy and fewer days on mechanical ventilation, they quickly develop tolerance to and have significant withdrawal from DEX. This necessitates protracted weaning of DEX and longer length of stay in the pediatric intensive care unit (PICU) since DEX can only be administered as a continuous intravenous (IV) infusion. CLON, on the other hand, has a longer half-life and has formulations that allow for continuous or intermittent IV and oral administration. Dr. Gauda has an approved IND to use the epidural formulation of CLON intravenously in infants and children. The purpose of this pilot study is to determine the effective IV dosing scheme of CLON that can be safely used as an adjunct to analgesic-sedation management for infants and children in the PICU. It will include a total of 24 infants and children with 4 CLON and DEX exposed in each age stratum: 0-3, 4-6, and 7-12 months. We hypothesize that IV CLON can achieve optimal sedation and reduce the need for opiate/BENZO therapy in critically ill infants and children who would otherwise receive DEX, and thus, reduce the length of stay in the PICU. Data from this study will be used to inform a larger randomized trial and will directly benefit infants and children in Baltimore who are critically ill. Funds are requested to cover the cost of the CLON drug levels and the investigational pharmacy.


Minimum age: N/A. Maximum age: 12 Months. Gender(s): Both.


Inclusion Criteria:

- Infants and children age: 0-12 months

- Intubated and mechanically ventilated in the JHH PICU

- Meet criteria for starting dexmedetomidine (per PICU protocol)

Exclusion Criteria:

- Postoperative from complex congenital heart disease

- Asphyxia

- Traumatic Brain Injury

- Major Chromosomal anomaly (Trisomy 13, 18)

- Any infant or child who is receiving ECMO therapy

- If death is considered imminent

Locations and Contacts

Estelle B Gauda, MD, Phone: 410-614-0151, Email: egauda@jhmi.edu

Johns Hopkins Hospital, Baltimore, Maryland 21287, United States; Not yet recruiting
Estelle B Gauda, MD, Phone: 410-614-0151, Email: egauda@jhmi.edu
Tarrah Ezell, BS, Phone: 410-614-0151, Email: Tezell1@jhmi.edu
Additional Information

Starting date: September 2015
Last updated: March 30, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017